Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

A recent study highlights the effectiveness of Semaglutide, an anti-diabetes drug, in reducing the risk of heart attacks and ...

Semaglutide can help lower the risk of cardiovascular complications in people with diabetes, a new study has found.

The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

The race is on to make the first oral weight loss medicines, but smaller US pharmacies may have already got there – if they ...

N) has reported new Phase IIIb data showing its GLP-1 drug semaglutide, in both oral and injectable forms, led to significant health benefits in adults with type 2 diabetes facing cardiovascular ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide ... Supported by Novo Nordisk. Disclosure forms provided by the authors are available with the full text of this article ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to ...